UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 4, 2014
Yew Bio-Pharm Group, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 000-54701 | 26-1579105 | ||
(State or other Jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
723 South Casino Center Blvd. Las Vegas, Nevada |
89101 | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (702) 487-4683
| 294 Powerbilt Avenue, Las Vegas, Nevada 89148 |
| (Former name or former address if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Information included in this Form 8-K may contain forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). This information may involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Yew Bio-Pharm Group, Inc. (herein referred to as the “Company” or “Registrant”), to be materially different from future results, performance or achievements expressed or implied by any forward-looking statements. Forward-looking statements, which involve assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words "may," "will," "should," "expect," "anticipate," "estimate," "believe," "intend" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are based on assumptions that may be incorrect, and there can be no assurance that any projections or other expectations included in any forward-looking statements will come to pass. The Company’s actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors. Except as required by applicable laws, the Company undertakes no obligation to update publicly any forward-looking statements for any reason, even if new information becomes available or other events occur in the future.
Section 7- Regulation FD
Item 7.01 Regulation FD Disclosure
On November 4, 2014, the Company issued a press release announcing the creation of a new subsidiary, Harbin Yew Food Co. LTD., to develop and cultivate black fungus. The Company plans to operate three production lines to include black fungus polysaccharide, powder, tea and other packaged black fungus products. The move marks the Company's entrance into the organic food and functional beverage market.
A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
This disclosure does not constitute an offer to sell, or the solicitation to buy, any such security.
Item 9.01 Financial Statements and Exhibits.
Exhibit Number |
Description | |
| 99.1 | Press release, dated November 4, 2014 of Yew Bio-Pharm Group, Inc. |
| 2 |
Signature(s)
Pursuant to the Requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the Undersigned hereunto duly authorized.
| Yew Bio-Pharm Group, Inc. | ||
| Date: November 5, 2014 | By: | /s/ Zhiguo Wang |
| Zhiguo Wang | ||
| President & Chief Executive Officer | ||
3
Exhibit 99.1
For Immediate Release:
Yew Bio-Pharm Establishes New Subsidiary to Focus on Organic Foods and Functional Beverages
Division to Concentrate on Black Fungus Cultivation and Development
HARBIN, China, Nov. 4, 2014 /PRNewswire via COMTEX/ -- Yew Bio-Pharm Group, Inc. ("Yew
Bio" or the "Company") (OTCBB:YEWB), today announced the creation
of a new subsidiary, Harbin Yew Food Co. LTD., to develop and cultivate black fungus. The company plans to operate three production
lines to include black fungus polysaccharide, powder, tea and other packaged black fungus products. The move marks the Company's
entrance into the organic food and functional beverage market.
Harbin Yew Food will utilize an area of 10,000 square meters for black fungus production workshops, which includes 1,500 square meters of warehouses, a 500 square meter factory building and 600 square meters of laboratories and offices.
Black fungus, also known as "Wood Ear" or "Cloud Ear" herb helps with health issues associated with the lungs, stomach and liver, according to the Institute of Chinese Medicine. Black fungus is rich in iron, protein, vitamins, polysaccharide, fiber, and other minerals, which often are used in Chinese cooking and traditional Chinese medicine.
"As common living standards and lifestyle advance in China, demand for healthcare and supplement products continue to rise rapidly," said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. "The expansion into black fungus leverages our experience in the cultivation and production of traditional Chinese medicine, providing for further diversification and creating another potential revenue stream."
According to a Chinese Health Food Industry Monitoring and Marketing Research Report, sales of vitamins and dietary supplements were estimated to be $84.26 billion in 2011, nearly 13% of which were sold in China. Furthermore, according to a forecast from China's Healthcare Association, sales of vitamins and dietary supplements in China are estimated to increase up to 10% annually.
ABOUT YEW BIO-PHARM GROUP, INC.
Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. Yew Bio-Pharm also recently established a division to focus on organic foods and dietary supplements. To learn more, please visit http://www.yewbiopharm.com.
SOURCE Yew Bio-Pharm Group, Inc.
http://rt.prnewswire.com/rt.gif?NewsItemId=CN56586&Transmission_Id=201411040930PR_NEWS_USPR_____CN56586&DateId=20141104
www.prnewswire.com